|
|
Post by mytakeonit on Aug 2, 2018 17:25:42 GMT -5
After ADA and the endos getting news of Afrezza ... takes a couple of months for scripts to start picking up. August script counts should start picking up soon.
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 2, 2018 17:27:39 GMT -5
Mike's most important part:
Progressing Towards Cash Flow Breakeven
Updated Net Revenue Guidance $22m-25m (Still pretty good IMHO, but I can hear Spencer now)
No Change to Net Cash Used in Operating Activities of $90m-100m
Potential Sources to Complete Recapitalization:
* Partnership(s) for Pipeline Assets
* International Licensing and Milestones
* Co-Promote Opportunities
* Debt; Convertible Debt
* Warrants Outstanding ~$33m
* Equity
Faster growth as people continue to adopt CGMs, and we gain additional countries beyond the US as well as the Pediatric program completion, Afrezza will continue to grow for years to come.
Our current focus now ... is to get to cash-flow breakeven as soon as possible.
We expect the predominant way that MNKD will get to cash-flow breakeven will be
1. through the business development activity we've listed on this slide (6 bullet-points above)
2. driving faster Afrezza Trial and Adoption
3. potential new debt opportunities given our asset base
At this point, we look to finish up the recapitalization plan that Steve and I started over a year ago and we believe this will put us on the pathway to cash-flow breakeven.
As you look at the options on the slide, you can see that there are many options to recapitalize the company, and we do not expect equity/continued dilution will be the predominant way we grow our cash-flow to breakeven.
|
|
|
|
Post by buyitonsale on Aug 2, 2018 17:29:09 GMT -5
Investor conferences in September = capital raise around that time?
Equity was listed as the last item on recapitalization slide, but we have seen this before... still no clarity.
|
|
|
|
Post by derek2 on Aug 2, 2018 17:40:44 GMT -5
at 50:30 - gross profit per unit will turn positive in 2nd half 2018. So each unit sold will contribute to covering non-COGS costs.
That's very positive news, IMO.
Yep, I'm still around.
Last A1C 7.2 thanks to the data provided by my Libre. Down from 8.9
|
|
|
|
Post by babaoriley on Aug 2, 2018 17:46:46 GMT -5
WESTLAKE VILLAGE, Calif. (AP) _ MannKind Corp. (MNKD) on Thursday reported a loss of $22.7 million in its second quarter. On a per-share basis, the Westlake Village, California-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $3.9 million in the period. I n the final minutes of trading on Thursday, the company's shares hit $1.50. A year ago, they were trading at $1.19.Where in the world did the fake news in bold come from? |
|
|
|
Post by mytakeonit on Aug 2, 2018 18:11:19 GMT -5
Carmen San Diego
|
|
|
|
Post by peppy on Aug 2, 2018 18:22:17 GMT -5
at 50:30 - gross profit per unit will turn positive in 2nd half 2018. So each unit sold will contribute to covering non-COGS costs. That's very positive news, IMO.Yep, I'm still around. Last A1C 7.2 thanks to the data provided by my Libre. Down from 8.9thank you for your take. additionally, one day, will you tell us the changes you made with the help of the libre? |
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 2, 2018 18:26:24 GMT -5
at 50:30 - gross profit per unit will turn positive in 2nd half 2018. So each unit sold will contribute to covering non-COGS costs. That's very positive news, IMO. Yep, I'm still around. Last A1C 7.2 thanks to the data provided by my Libre. Down from 8.9 Hi Derek. Nice to see your smiling face around again (antlers and all) ;o) And, good job on the A1C. Keep up the good work. Al would say "not good enough". Keep shooting for 6. I had to go back and listen to that again. Here's what I got from it: Warren: On the numbers front again, what are the underlying gross margins separating out fixed overhead vs. variable cost, what would be the break-even on a production or gross-profit basis. What sales level would that take at current pricing and gross net these days? Steve: We certainly have costs in excess of our standard now, as we are not running at full capacity. Not only on our production line, but in our entire manufacturing facility. I would expect that our negative gross profit today will turn positive sometime in the second half of 2018. I can't tell you exactly when that will happen, it all depends on when we do production runs, which take costs and put it out to inventory ... but, I expect it to happen sometime in the second half. |
|
|
|
Post by mango on Aug 2, 2018 19:41:19 GMT -5
|
|
|
|
Post by seanismorris on Aug 2, 2018 19:55:49 GMT -5
The most interesting thing I heard was about taxes. They were talking about recapitalization at the time (waiting on transcript).
I was invested in another med company that had cash and a product, who merged with another company that had a pipeline with little cash.
MannKind could merge with a company that could take advantage of MannKinds tax situation. I’m not talking about MannKind selling out, but acquiring someone with cash flow. MannKind probably wouldn’t have a problem with funding if there was some synergy. Maybe someone using a contracted sales force...
|
|
|
|
Post by morgieporgie on Aug 2, 2018 19:58:18 GMT -5
Way too long to learn, souble the time they would expect. FAIL |
|
|
|
Post by seanismorris on Aug 2, 2018 20:06:11 GMT -5
Way too long to learn, souble the time they would expect. FAIL I think you’re taking it out of context. What it’s saying is it takes a doc 1 to 1.5 to learn about & how to prescribe Afrezza, but the doctor are staying longer to discuss the paradigm shift that is Afrezza + Diabetes care. |
|
|
|
Post by morgieporgie on Aug 2, 2018 20:10:34 GMT -5
Way too long to learn, souble the time they would expect. FAIL I think you’re taking it out of context. What it’s saying is it takes a doc 1 to 1.5 to learn about & how to prescribe Afrezza, but the doctor are staying longer to discuss the paradigm shift that is Afrezza + Diabetes care. Or enjoy the party and overspending management seems to be doing - like on the leases. |
|
|
|
Post by brotherm1 on Aug 2, 2018 20:23:11 GMT -5
Nonsence. Why comment when you don’t know the full terms of the lease (e.g., how much down, how much due at the end of lease if any, how it might be an inexpensive perk for sales staff considering current salaries and benefits? Why comment, especially negatively, without knowing the facts? Why?
|
|
|
|
Post by sayhey24 on Aug 2, 2018 20:23:27 GMT -5
If Mike and Dr. Kendall spend twice what they expected for a dinner and get one Endo who can write 10 scripts a week I would say money very well spent and a home run. However, if that one Endo brought eight endo friends who came for the free dinner, find out Dr. Kendall actually showed up and not some sales guy and now we have nine new Endo's writing scripts, well that's a grand-slam.
I will be honest my truck lease is more than what MNKD is paying per car so I can't be critical of the $540 per month but its a really nice truck.
If what Mike and Steve said today is true and they make good on their predictions, MNKD is way ahead of the schedule I had. If they can really keep paying the electric bill without significant future dilution that's another grand-slam which I was not expecting but will gladly take.
|
|
